My goal is to help you evaluate longevity biotech companies better. I’ve picked the ideas from my research that I think will be most useful when you encounter companies using these or related approaches, so you can understand the pitch, ask better questions and judge the evidence.
Could cells collected from menstrual blood become an ingredient for skincare, or the starting point for treatments that repair damaged tissue?
That is the opportunity researchers and companies are exploring. The interesting part is what these cells make and release: biological signals that can influence other cells.
By the end of this lesson, you will understand the three product approaches, how their signals work, what studies have shown, and where the commercial opportunity could be.
1. Start With The Product
Menstrual fluid contains cells shed from the uterine lining. Researchers can collect it, isolate selected stromal cells, which help support and maintain tissue, and grow them in a laboratory. From that starting point, there are three product approaches:
Living cells: give the cells themselves, which can release signals in the tissue.
Secretome: collect the mixture of substances the cells release.
Extracellular vesicles, or EVs: separate the tiny packages released by cells, each enclosed in a thin, fatty outer layer. “Extracellular” simply means outside the cell.
A real commercial example: Muse Bio describes a menstrual-derived, cell-free conditioned-media ingredient for skincare formulators, supplied in liquid or freeze-dried form. Think of an ingredient a brand could put into a serum, rather than living cells in a bottle. “Conditioned media” means the liquid collected after the cells have grown in it. Company product description.
Other possible products include local EV treatments for wounds, uterine injury or cartilage damage. These are being investigated in different experimental settings:
Skin Repair: Studies In Mice And Rats. Menstrual-cell EV injections improved wound closure and new blood-vessel formation in a mouse burn study. A newer study combined EVs with platelet-rich fibrin, a blood-derived scaffold, and reported improved wound healing in rats. The goal is a treatment that helps difficult wounds close and stay healed. Relevance to humans: this tests repair in a living body, but rodent skin relies more on pulling wound edges together than human skin does. Ask whether researchers measured new tissue formation as well as wound closure, and whether the wound resembles the condition the company plans to treat. Why the wound model matters. Mouse study · Rat study
Uterine Repair: A Study In Rats. A small-EV treatment reduced scarring and improved uterine tissue and pregnancy outcomes after injury. The potential use is repairing a damaged uterine lining. Relevance to humans: reduced scarring and improved pregnancy outcomes are useful signals for this specific repair problem. They do not establish improved fertility in women or general rejuvenation. Look for tests in human tissue and then patients with the intended condition. Study
Cartilage Repair: A Study Using Human Cells And Tissue In The Lab. A 2026 study found encouraging production and preservation of the material that gives cartilage its structure. Relevance to humans: using human cartilage helps answer whether human tissue can respond. Tissue in a dish cannot tell us whether treatment reaches the right place in a living joint, lasts, reduces pain or improves walking. Those are the next questions. Study
Current position: a commercial skincare ingredient and promising experimental repair approaches. The clinical opportunity is to demonstrate useful, lasting benefits in patients.
2. How Could It Work?
Think of the cells as factories. They release substances that communicate with surrounding cells. The whole collection of released material is called the secretome.
Some signals are dissolved in the surrounding liquid. Others travel inside tiny packages called extracellular vesicles (EVs). EVs are part of the secretome.
The treatment idea is to collect useful signals and deliver them where tissue needs help. A receiving cell may then change its activity: survive an injury, form blood vessels, adjust inflammation or produce supporting tissue.
Three Kinds Of Molecules To Understand
Proteins are the body’s working crew. They are chains of building blocks called amino acids that fold into three-dimensional shapes. Their shapes help determine their jobs, such as building structures, speeding up chemical reactions or carrying messages. Here, some may send signals that help nearby cells survive damage or repair tissue.
RNA helps cells make proteins. Think of it as instructions and controls: some RNA tells a cell which protein to make; other RNA helps turn production down.
Lipids are fats and fat-like substances. They form the thin outer layer around each tiny package, holding its contents together and helping it interact with other cells.
These molecules work together. The useful question is: which signal changes which cell behavior, and does that produce the benefit we want?
EVs: The Packages
An EV is a tiny package released by a cell. An exosome is a particular type formed inside the cell before release. You will see “exosomes” used widely in company descriptions; EV is the broader term. Scientific terminology.
This is a whole field beyond menstrual-derived cells. Companies such as Evox are engineering exosome-based delivery systems. Researchers also study EVs from bone marrow, fat and umbilical-cord cells. Menstrual-derived cells offer another source, with cargo shaped by the source cells and how they are grown.
One Example Makes The Mechanism Concrete
In a rat ovarian-injury study, researchers examined menstrual-cell exosomes carrying a protein called thrombospondin-1. The treatment supported signals that help cells survive and improved ovarian and pregnancy outcomes. When researchers reduced that protein, the benefits weakened. Relevance to humans: the rats had chemically induced ovarian damage. This helps test how the treatment might work after that type of injury; it does not show that it reverses natural ovarian aging in women. Study.
That experiment connects the dots: a specific cargo → a change in cell behavior → a tissue outcome. It gives scientists something to investigate and improve, beyond simply saying “stem-cell signals are good.”
3. Why Use Menstrual-Derived Cells?
The uterine lining repeatedly grows, sheds and repairs. Menstrual fluid provides access to cells associated with that renewing tissue, through repeatable collection without a surgical harvest.
Scientists can select and expand those cells, then collect their secretions. Experimental comparisons have found encouraging growth and blood-vessel-related activity. Cell-source study.
The appeal is a renewable cell source that already makes biological signals and packages some of them into EVs. Researchers can work with that natural production system rather than design every component from scratch.
What makes a product distinctive is its measured cargo and activity. In one study, changing oxygen levels and inflammatory conditions changed the proteins in menstrual-cell EVs. The growing conditions therefore become part of the company’s technology. Study.
4. What Could The Opportunity Be Worth?
Skincare offers ingredient sales to brands. Wound care offers a medical application if a product improves healing. Reproductive medicine and joint disease offer further opportunities if the early tissue effects translate into patient benefits.
The underlying needs are substantial. For example, WHO estimated that 528 million people had osteoarthritis worldwide in 2019. A cartilage product would address a defined subset of that population. WHO.
To turn that need into a revenue estimate, use: eligible customers × realistic adoption × annual revenue per customer. For illustration only, 10,000 customers at $1,000 per year would generate $10 million in annual revenue. That is an arithmetic example, not a forecast for this field or a company valuation.
The company’s job is to define its first product, show a meaningful advantage, manufacture it consistently and establish a route to customers. A useful starting ingredient can become a business; broader medical uses require their own development.
Test Your Understanding
Use The Human Cartilage Study Above. Answer the five questions below in your own words before reading my answers. You are evaluating this experimental preparation, not every company using menstrual-derived cells.
What exactly was tested?
What is supposed to make it work, and what remains unexplained?
What makes the results relevant to people, and what human benefit was not measured?
What does the study tell us about delivery and safety in a person?
Does it establish that a company can manufacture a consistent treatment?
Compare With My Answers
Product: separated extracellular vesicles from cultured menstrual-derived cells, applied to human cartilage cells and tissue in the laboratory. This was not a living-cell treatment given to patients.
Mechanism: the preparation encouraged production or preservation of cartilage material. The exact contents responsible still need to be identified.
Human Relevance: the study used human tissue, including cartilage from older women with osteoarthritis. It did not measure pain relief, walking or lasting benefit in treated patients.
Delivery And Safety: laboratory exposure does not establish a safe dose, delivery or long-term safety in a living joint.
Consistency: a laboratory preparation is a starting point. This study does not establish reliable commercial production across batches.
Give Yourself A Grade
For each answer: 2 points for the main answer and its limitation; 1 point if you understood part but missed something important; 0 points if you could not explain it or assumed a result the study did not show.
9–10: Strong Understanding · 7–8: Good Foundation · 5–6: Review What You Missed · 0–4: Reread And Try Again.
Your score measures understanding of this case, not company quality or readiness to invest. Rewrite one answer you missed in your own words.